|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Centre de Recherche en Rhumatologie et Immunologie, Centre de Recherche du CHUQ-CHUL (C.Z., M.T.), Départements d'Anatomie-Physiologie (M.J.F., S.G.B.) et Médecine, Facultéde Médecine (P.E.P.), Université Laval, Québec, Canada; Département de Rhumatologie et Immunologie, Centre Universitaire McGill, Montréal, Québec, Canada (J.D.B.); Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (T.C.); and Department of Medical Chemistry, the University of Utah, Salt Lake City, Utah (G.D.P.)
Lysophosphatidic acid (LPA), via interaction with its G-protein coupled receptors, is involved in various pathological conditions. Extracellular LPA is mainly produced by the enzyme autotaxin (ATX). Using fibroblast-like synoviocytes (FLS) isolated from synovial tissues of patients with rheumatoid arthritis (RA), we studied the expression profile of LPA receptors, LPA-induced cell migration, and interleukin (IL)-8 and IL-6 production. We report that FLS express LPA receptors LPA1-3. Moreover, exogenously applied LPA induces FLS migration and secretion of IL-8/IL-6, whereas the LPA3 agonist L-sn-1-O-oleoyl-2-methyl-glyceryl-3-phosphothionate (2S-OMPT) stimulates cytokine synthesis but not cell motility. The LPA-induced FLS motility and cytokine production are suppressed by LPA1/3 receptor antagonists diacylglycerol pyrophosphate and (S)-phosphoric acid mono-(2-octadec-9-enoylamino-3-[4-(pyridine-2-ylmethoxy)-phenyl]-propyl) ester (VPC32183). Signal transduction through p42/44 mitogen-activated protein kinase (MAPK), p38 MAPK, and Rho kinase is involved in LPA-mediated cytokine secretion, whereas LPA-induced cell motility requires p38 MAPK and Rho kinase but not p42/44 MAPK. Treatment of FLS with tumor necrosis factor-
(TNF-
) increases LPA3 mRNA expression and correlates with enhanced LPA- or OMPT-induced cytokine production. LPA-mediated superproduction of cytokines by TNF-
-primed FLS is abolished by LPA1/3 receptor antagonists. We also report the presence of ATX in synovial fluid of patients with RA. LPA1/3 receptor antagonists and ATX inhibitors reduce the synovial fluid-induced cell motility. Together the data suggest that LPA1 and LPA3 may contribute to the pathogenesis of RA through the modulation of FLS migration and cytokine production. The above results provide novel insights into the relevance of LPA receptors in FLS biology and as potential therapeutic targets for the treatment of RA.
Address correspondence to: Dr. Sylvain G. Bourgoin, Centre de Recherche en Rhumatologie et Immunologie, Local T1-49, Centre de Recherche du CHUQ-CHUL, 2705 Boul. Laurier, Québec, Canada, G1V 4G2. E-mail: sylvain.bourgoin{at}crchul.ulaval.ca
This article has been cited by other articles:
![]() |
C. Zhao, M. J. Fernandes, M. Turgeon, S. Tancrede, J. Di Battista, P. E. Poubelle, and S. G. Bourgoin Specific and overlapping sphingosine-1-phosphate receptor functions in human synoviocytes: impact of TNF-{alpha} J. Lipid Res., November 1, 2008; 49(11): 2323 - 2337. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nochi, H. Tomura, M. Tobo, N. Tanaka, K. Sato, T. Shinozaki, T. Kobayashi, K. Takagishi, H. Ohta, F. Okajima, et al. Stimulatory Role of Lysophosphatidic Acid in Cyclooxygenase-2 Induction by Synovial Fluid of Patients with Rheumatoid Arthritis in Fibroblast-Like Synovial Cells J. Immunol., October 1, 2008; 181(7): 5111 - 5119. [Abstract] [Full Text] [PDF] |
||||